Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) EVP Andrew Callos sold 15,000 shares of the firm's stock in a transaction that occurred on Thursday, April 30th. The stock was sold at an average price of $63.26, for a total transaction of $948,900.00. Following the sale, the executive vice president owned 58,555 shares in the company, valued at approximately $3,704,189.30. This trade represents a 20.39% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Andrew Callos also recently made the following trade(s):
- On Wednesday, April 15th, Andrew Callos sold 7,449 shares of Cytokinetics stock. The stock was sold at an average price of $66.02, for a total transaction of $491,782.98.
- On Wednesday, March 18th, Andrew Callos sold 1,930 shares of Cytokinetics stock. The stock was sold at an average price of $62.07, for a total transaction of $119,795.10.
- On Tuesday, March 17th, Andrew Callos sold 8,542 shares of Cytokinetics stock. The stock was sold at an average price of $62.15, for a total transaction of $530,885.30.
- On Monday, March 16th, Andrew Callos sold 1,709 shares of Cytokinetics stock. The stock was sold at an average price of $61.03, for a total transaction of $104,300.27.
- On Monday, March 9th, Andrew Callos sold 2,582 shares of Cytokinetics stock. The stock was sold at an average price of $60.72, for a total transaction of $156,779.04.
- On Thursday, March 5th, Andrew Callos sold 26,000 shares of Cytokinetics stock. The stock was sold at an average price of $61.87, for a total transaction of $1,608,620.00.
- On Thursday, February 5th, Andrew Callos sold 15,000 shares of Cytokinetics stock. The stock was sold at an average price of $61.93, for a total transaction of $928,950.00.
- On Monday, February 2nd, Andrew Callos sold 886 shares of Cytokinetics stock. The stock was sold at an average price of $62.10, for a total transaction of $55,020.60.
Cytokinetics Stock Performance
Shares of NASDAQ CYTK opened at $63.97 on Friday. Cytokinetics, Incorporated has a 1 year low of $29.31 and a 1 year high of $70.98. The firm's 50 day moving average price is $63.81 and its 200 day moving average price is $63.49. The firm has a market cap of $7.95 billion, a P/E ratio of -9.80 and a beta of 0.47.
Cytokinetics (NASDAQ:CYTK - Get Free Report) last announced its earnings results on Tuesday, February 24th. The biopharmaceutical company reported ($1.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.48) by ($0.02). The company had revenue of $17.76 million for the quarter, compared to analysts' expectations of $8.02 million. During the same quarter in the prior year, the business posted ($1.26) EPS. The business's revenue was up 4.9% compared to the same quarter last year. As a group, equities analysts predict that Cytokinetics, Incorporated will post -6.22 EPS for the current year.
Analysts Set New Price Targets
CYTK has been the topic of a number of research analyst reports. Needham & Company LLC lifted their price target on shares of Cytokinetics from $84.00 to $85.00 and gave the company a "buy" rating in a report on Wednesday, February 25th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Cytokinetics in a report on Monday, April 20th. JPMorgan Chase & Co. lifted their price target on shares of Cytokinetics from $74.00 to $75.00 and gave the company an "overweight" rating in a report on Tuesday, March 17th. Mizuho lifted their price target on shares of Cytokinetics from $84.00 to $100.00 and gave the company an "outperform" rating in a report on Wednesday, March 18th. Finally, Truist Financial lifted their price target on shares of Cytokinetics from $84.00 to $92.00 and gave the company a "buy" rating in a report on Tuesday, February 3rd. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Cytokinetics presently has a consensus rating of "Moderate Buy" and an average price target of $90.55.
Check Out Our Latest Research Report on CYTK
Hedge Funds Weigh In On Cytokinetics
Hedge funds and other institutional investors have recently made changes to their positions in the business. EverSource Wealth Advisors LLC lifted its holdings in shares of Cytokinetics by 723.7% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 766 shares of the biopharmaceutical company's stock valued at $25,000 after acquiring an additional 673 shares in the last quarter. Kemnay Advisory Services Inc. acquired a new position in shares of Cytokinetics during the 4th quarter valued at $27,000. Kestra Advisory Services LLC acquired a new position in shares of Cytokinetics during the 4th quarter valued at $29,000. Quarry LP acquired a new position in shares of Cytokinetics during the 3rd quarter valued at $30,000. Finally, TD Waterhouse Canada Inc. acquired a new position in shares of Cytokinetics during the 4th quarter valued at $32,000.
About Cytokinetics
(
Get Free Report)
Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.
The company's most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
